ArriVent BioPharma's stock dropped more than 50% after its Phase 3 FURVENT trial for firmonertinib failed to meet the primary endpoint of progression-free survival in lung cancer patients. This setback comes just five months after the company raised $250 million through a stock offering. The failure has triggered an investigation into possible misleading statements by the company regarding the trial's prospects. Investors who bought shares at inflated prices may be eligible to recover losses through legal action.
ArriVent BioPharma's recent trial failure and investigation notice provide context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Oct 07, 2026 04:23 WIB: out of 100 priced health-sector US stocks, 41 rose and 59 fell. Among notable movers, Illumina, Inc. gained 7.68% to USD 294.00 with 78% buy orders and a typical hold time of 84 days, contrasting with Adaptive Biotechnologies Corp which dropped 9.65% to USD 26.96 despite 87% buy orders and a 36-day hold time, while Citius Pharmaceuticals Inc fell 7.65% to USD 0.48 but saw 98% buy orders and a shorter 17-day hold time.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
